Table 1. Characteristics of the primary study cohorts.
| Mean PMI (Hours) | Mean CDR | Mean Age | Sex | Mean Cortical Plaques per mm^2 | Mean Braak & Braak Score | Race (white; Black; Hispanic | Mean Blood glucose (mg/dl) | |
| Control (N = 30) | 12.85 (1.4) | 0.43 (0.13) | 83.17 (1.48) | 14F; 16M | 0.83 (0.32) | 1.5 (0.32) | 26; 3; 1 | 95.5 (22) |
| AD (N = 19)* | 6.88 (1.17) | 3.0 (0.28) | 88.26 (2.01) | 15F; 4M | 9.58 (1.38) | 4.89 (0.29) | 17; 2; 1 | 119.4 (8) |
| AD+DM+Meds (N = 34)* | 7.67 (0.98) | 2.89 (0.26) | 84.61 (1.49) | 23F; 11M | 8.39 (0.86) | 4.64 (0.26) | 26; 5; 3 | 148.8 (14) |
| Medication Characteristics of the AD+DM+Meds (N = 34 cohort) | ||||||||
| Medication Subset | Percent of Subset | Medication class | ||||||
| Insulin Only | N = 15 (45%) | Insulin | ||||||
| Oral Only | N = 12 (35%) | N = 9 (75%) Sulfonylurea N = 2 (17%) Metformin N = 1 (8%) Thiazolidinedione |
||||||
| Insulin + Oral | N = 7 (21%) | N = 5 (79%) Sulfonylurea N = 2 (21%) Metformin |
||||||
* 17% (N = 9) of cases with AD (with or without DM medications) were treated with medications for AD (one was treated with memantine and 8 received donepezil) which were terminated at least 14 months prior to death.